NCT01880827

Brief Summary

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems. Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI \> 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis. The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P50-P75 for phase_1 type-2-diabetes

Timeline
Completed

Started Jan 2013

Longer than P75 for phase_1 type-2-diabetes

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 25, 2013

Completed
4 months until next milestone

First Posted

Study publicly available on registry

June 19, 2013

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2015

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
Last Updated

October 20, 2021

Status Verified

October 1, 2021

Enrollment Period

2.8 years

First QC Date

February 25, 2013

Last Update Submit

October 12, 2021

Conditions

Keywords

GIPGLP-1type 2 diabetesobesitysplanchnic blood flowincretin hormones

Outcome Measures

Primary Outcomes (1)

  • Splanchnic blood flow

    Flow is measured using radiowater H2O and PET

    24 months

Secondary Outcomes (1)

  • GIP and GLP-1 blood concetrations

    24 months

Study Arms (3)

Royx-en-Y surgery

ACTIVE COMPARATOR

Mixed meal test (MMS) with flow studies before and 2 months after the operation

Procedure: Roux-en-YDrug: GIP-infusionDrug: MMS

Control

ACTIVE COMPARATOR

Healthy volunteer group, GIP, GLP-1 and MMS studies

Drug: GIP-infusionDrug: GLP-1Drug: MMS

Sleeve gastrectomy

EXPERIMENTAL

Mixed meal test (MMS) with flow studies before and 2 months after the operation

Drug: GIP-infusionDrug: MMSProcedure: Sleeve gastrectomy

Interventions

Roux-en-YPROCEDURE

Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.

Royx-en-Y surgery

Blood flow and volume during infusion

ControlRoyx-en-Y surgerySleeve gastrectomy
GLP-1DRUG

Blood flow and volume during infusion

Control
MMSDRUG

Blood flow and volume after meal solution

ControlRoyx-en-Y surgerySleeve gastrectomy

as in RYGS group

Sleeve gastrectomy

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI \> 35 kg/m2
  • Type 2 diabetes mellitus (fasting glucose more than 7 mmol/l)
  • Age: 18-60 years
  • Previous, carefully planned, conservative treatments for obesity have failed

You may not qualify if:

  • BMI over 60 kg/m2
  • Weight more than 170 kg
  • Waist circumference \> 150 cm
  • Insulin treatment requiring type 2 diabetes mellitus
  • Mental disorder or poor compliance
  • Eating disorder or excessive use of alcohol
  • Active ulcus-disease
  • Pregnancy
  • Past dose of radiation
  • Presence of any ferromagnetic objects that would make MR imaging contraindicated
  • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
  • BMI 18-27 kg/m2
  • Age 18-60 years
  • Fasting plasma glucose less than 6.1 mmol/l
  • Normal glucose tolerance test (OGTT)
  • +10 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Turku univercity hospital, PET center

Turku, 20540, Finland

Location

Related Publications (2)

  • Saari T, Koffert J, Honka H, Kauhanen S, U-Din M, Wierup N, Lindqvist A, Groop L, Virtanen KA, Nuutila P. Obesity-associated Blunted Subcutaneous Adipose Tissue Blood Flow After Meal Improves After Bariatric Surgery. J Clin Endocrinol Metab. 2022 Jun 16;107(7):1930-1938. doi: 10.1210/clinem/dgac191.

  • Honka H, Koffert J, Kauhanen S, Teuho J, Hurme S, Mari A, Lindqvist A, Wierup N, Groop L, Nuutila P. Bariatric Surgery Enhances Splanchnic Vascular Responses in Patients With Type 2 Diabetes. Diabetes. 2017 Apr;66(4):880-885. doi: 10.2337/db16-0762. Epub 2017 Jan 17.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Obesity

Interventions

Anastomosis, Roux-en-YGlucagon-Like Peptide 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Anastomosis, SurgicalSurgical Procedures, OperativeDigestive System Surgical ProceduresGlucagon-Like PeptidesProglucagonGastrointestinal HormonesHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

  • Pirjo Nuutila, Prof

    PET centre, Turku

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 25, 2013

First Posted

June 19, 2013

Study Start

January 1, 2013

Primary Completion

November 1, 2015

Study Completion

January 1, 2016

Last Updated

October 20, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations